AMAL Therapeutics to publish research outcomes in Cancers
Geneva, Switzerland, October 20, 2022 – AMAL Therapeutics is pleased to announce that the latest findings of its research team is online on the Cancers website.
Laetitia Devy Dimanche takes over CEO position on September 1st, 2022
Geneva - September 1st, 2022 - Laetitia Devy Dimanche is taking over CEO position from Madiha Derouazi
Madiha Derouazi and Elodie Belnoue honoured at the European Inventor Award 2022 ceremony
Geneva - 21 June 2022 - Congratulations to Madiha Derouazi & Elodie Belnoue for winning the "SMEs" category at the European InventorAward 2022!
Madiha Derouazi and Elodie Belnoue named as joint finalists for European Inventor Award 2022
Geneva, 17 May 2022 – We are very happy and proud to announce that Madiha Derouazi and Elodie Belnoue have been jointly nominated for the EPO's European Inventor Award 2022.
Joint Team Effort Succeeds in Advancing First-in-Cass Triple Combination Immunotherapy to Studies in Patients with Colorectal Cancer
AMAL Therapeutics and ViraTherapeutics, in partnership with their common parent company, Boehringer Ingelheim, are very proud to announce that they have advanced their first-in-class heterologous prime-boost vaccine to Phase 1 studies in patients with colorectal cancer in combination with Ezabenlimab (BI 754091).


You are now leaving our website

Using this link will let you leave a website of Amal Therapeutics or to a different domain under the control of Amal Therapeutics. In the event that the linked site is not under the control of Amal Therapeutics but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, Amal Therapeutics shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites.

This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Amal Therapeutics of the site.

Target URL: